News
Media Coverage
-
- 25
- 2022/08
People Daily Health｜Sino Biopharm Releases Semi-annual Report, Aims at 100 Billion Revenue in 2030
"The company will achieve its strategic goal of HK$100 billion revenue by 2030 through comprehensive innovation and transformation driven by independent research and development and external introduction. 79 products are expected to be launched in the next three years," said Miss Tse, Theresa Y Y, Chairwoman of the Board of Directors of Sino Biopharm.View > -
- 25
- 2022/08
Takungpao｜Sino Biopharm's New CEO Makes his Debut and Promotes Operational Reform
Hang Seng Index constituent Sino Biopharm (HK0.1177) held its first half-year results conference and the first investor day in Beijing on August 24th, where the new CEO Mr. Tse, Eric S Y made his debut.View > -
- 09
- 2022/03
CHINADAILY｜Sino Biopharm announces clinical trials for pneumoconiosis drug
Sino Biopharmaceutical Limited, or Sino Biopharm, a leading innovative research and development-driven pharmaceutical conglomerate in China, announced on Tuesday that TDI01 suspension, an innovative drug independently developed by its subsidiary Beijing Tide Pharmaceutical Co Ltd, had received approval from the National Medical Products Administration for clinical trials on treating pneumoconiosis, a key occupational disease in China that affects the lungs and is caused by inhalation of dust.View > -
- 21
- 2021/05
“Aprepitant Capsules” obtains Drug Registration Certificate
Recently, “Aprepitant Capsules” (brand name: “Shanyi” (善依)) (approved specifications: 80mg and 125mg), an adjuvant drug for tumor treatment developed by the Group, has obtained the drug registration certificate from the National Medical Products Administration of the People’s Republic of China.View > -
- 13
- 2021/05
“Dasatinib Tablet” Passes Consistency Evaluation
Recently, “Dasatinib Tablet” (product name: Yinishu) (specifications: 20mg and 50mg), an oncology medicine developed by the Group, has obtained the notice of approval of supplemental application on pharmaceutical product issued by the National Medical Products Administration of the People’s Republic of China,View > -
- 13
- 2021/05
“Palonosetron Hydrochloride Injection” Passes Consistency Evaluation
Recently, “Palonosetron Hydrochloride Injection” (Product name “Zhiruo”) (specifications: 5ml: 0.25mg and 1.5ml: 0.075mg), a drug developed by the Group, for the prevention of nausea and vomiting caused by chemotherapy has obtained the notice of approval of supplemental application on pharmaceutical product issued by the National Medical Products Administration of the People’s Republic of China, and passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs.View > -
- 29
- 2021/03
“Fosaprepitant Dimeglumine for Injection” obtains FDA ANDA Approval
Recently,“Fosaprepitant Dimeglumine for Injection” (brand name “Shanqi”), a drug developed by the Group used for the prevention of nausea and vomiting caused by chemotherapy, has obtained approval of abbreviated new drug application (“ANDA”, i.e. United States generic drug application) from the United States Food and Drug Administration (“FDA”).View > -
- 24
- 2021/03
Acquistion of Softhale
Recently, Sino Biopharm announced that on 22 March 2021, C-Lab International Limited, a wholly-owned subsidiary of the Company, entered into an agreement in relation to a 100% acquisition of SOFTHALE NV for US$110 million and additional payments related to regulatory and commercial milestones.View > -
- 10
- 2021/02
“Paricalcitol Injection” obtains Drug Registration Certificate
Recently, “Paricalcitol Injection” (Brand name: Kai Sha), a nephrology drug developed by the Group, has obtained drug registration certificate granted by the National Medical Products Administration of the People’s Republic of China.View >